WNT pathway modulators

A method of modulating WNT activity comprising exposing a WNT protein or a WNT receptor to an effective amount of a compound of formula (I)

• or a pharmaceutically acceptable salt, solvate, polymorph, tautomer, or stereoisomer thereof wherein:
• R1 represents H;
• alkyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkoxy, NH2, —NHC1-3alkyl, and —N(C1-3alkyl)2;
• —C(O)Oalkyl;
• haloalkyl;
• haloalkoxy;
• or -alkylaryl;
• each R2 independently represents H;
• alkyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkoxy, NH2, —NHC1-3alkyl, and —N(C1-3alkyl)2;
• -alkylaryl;
• carbocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo;
• heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, —C(O)OC1-6alkyl, —C(O)C1-6alkyl, and —C(O)NHC1-6alkyl;
• —NHalkyl;
• —N(alkyl)2;
• amino;
• hydroxyl;
• alkoxy;
• or halo;
• n represents 0, 1, or 2;
• R3 represents H or alkyl;
• R4 represents H or alkyl;
• R5 represents H or alkyl;
• W and X each independently represent C═O;
• C═S;
• or CH2;
• Y represents aryl;
• heteroaryl;
• carbocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy, and halo;
• or heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, —C(O)OC1-6alkyl, —C(O)C1-6alkyl, and —C(O)NHC1-6alkyl;
• and
• Z represents alkyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkoxy, NH2, —NHC1-3alkyl, and —N(C1-3alkyl)2;
• aryl;
• heteroaryl;
• -alkylaryl;
• -alkylheteroaryl;
• carbocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy, and halo;
• heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, —C(O)OC1-6alkyl, —C(O)C1-6alkyl, and —C(O)NHC1-6alkyl;
• -alkylcarbocyclyl, wherein carbocyclyl is optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, C1-6haloalkoxy and halo;
• -alkylheterocyclyl wherein heterocyclyl is optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, —C(O)OC1-6alkyl, —C(O)C1-6alkyl, and —C(O)NHC1-6alkyl;
• -arylcarbocyclyl wherein carbocyclyl is optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, C1-6haloalkoxy, and halo;
• or -arylheterocyclyl wherein heterocyclyl of the -arylheterocyclyl is optionally substituted with one or more substituents each independently selected from the group consisting of C1-6alkyl, —C(O)OC1-6alkyl, —C(O)C1-6alkyl, and —C(O)NHC1-6alkyl.